ERBB2 and breast carcinoma: Furthermore, our analysis did not reveal a significant association between CLDN8 levels and overall survival (OS) in the studied cohort (p = 0.274) (Figure 1D), nor did it substantiate the role of CLDN8 as a determinant of DFS in either ER(+) (p = 0.432) (Figure 1E) or HER2(+) (p = 0.349) (Figure 1F)breast cancer patients.